|
A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease Clinical research trials and A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease. A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease clinical trial. Human subjects frequently get the finest healthcare available for their A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease
A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease
For Condition: Parkinson Disease
Status: No longer recruiting
Sponsor(s): Pfizer ,
Synopsis: Double-blind fixed dose study evaluating an investigational drug in early Parkinson's Disease
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 30 Years/
Genders: Both
Protocol Entry Criteria: Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: - Idiopathic Parkinson's disease < 7 years duration - Modified Hoehn and Yahr Scale Stages I, II, or III - Age greater than or equal to 30 years old - Patients or their partners must use adequate contraceptive methods - Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures and do not plan on traveling extensively during the study Exclusion Criteria: - Atypical Parkinson's disease syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases - Levodopa received for 1-year accumulated interval in the previous 2 years - Levodopa, dopamine agonist medications or catechol-o-methyl transferase inhibitors in the 30 days prior to baseline - History of stereotaxic brain surgery - Positive hepatitis B (surface antigen) or hepatitis C (antibody) - Surgery within 180 days of baseline visit that would negatively impact on the patient participation in the study - Dementia - History of active epilepsy within the past year - Certain cardiac conditions - Significant liver or renal disease with defined laboratory criteria - Other laboratory abnormalities - Malignant Melanoma or history of treated melanoma - Electroconvulsive therapy in the previous 90 days prior to baseline - Lactating women - Having received other investigational drugs within the previous 30 days prior to baseline - Patient participating in other investigational drug studies
Total Enrollment:
Location and Contact Information:
Research Center
Frederick, Maryland, 21702
United States
Research Center
Las Vegas, Nevada, 89052
United States
Research Center
Sarasota, Florida, 34234
United States
Research Center
Decatur, Georgia, 30033
United States
Research Center
San Francisco, California, 94115
United States
Research Center
Houston, Texas, 77030
United States
Research Center
Maitland, Florida, 32751
United States
Research Center
Sellersville, Pennsylvania, 18960
United States
Research Center
Richmond, Virginia, 23294
United States
Research Center
Milwaukee, Wisconsin, 53202
United States
Research Center
Fort Collins, Colorado, 85624
United States
Research Center
Atlanta, Georgia, 30338
United States
Research Center
Springfield, Missouri, 65804
United States
Research Center
Englewood, Colorado, 80113
United States
Research Center
Miami, Florida, 33136
United States
Research Center
Kansas City, Kansas, 66160-7314
United States
Research Center
Charlotte, North Carolina, 28209
United States
Research Center
Dayton, Ohio, 45409
United States
Research Center
Wenatchee, Washington, 98801
United States
Research Center
San Antonio, Texas, 78229
United States
Research Center
Spokane, Washington, 99204
United States
Research Center
Southfield, Michigan, 48034
United States
Research Center
Hartford, Connecticut, 06106
United States
Research Center
San Francisco, California, 94109
United States
Research Center
Huntsville, Alabama, 35801
United States
Research Center
Walnut Creek, California, 94598
United States
Research Center
Springfield, Missouri, 65807
United States
Research Center
Cleveland, Ohio, 44195
United States
Research Center
Elkhart, Indiana, 46514
United States
Research Center
Lebanon, New Hampshire, 03766
United States
Research Center
Bronx, New York, 10461
United States
Research Center
Albany, New York, 12208
United States
Research Center
Birmingham, Alabama, 35249
United States
Research Center
Baltimore, Maryland, 21201
United States
Research Center
Fairfield, Connecticut, 06430
United States
Research Center
Clearwater, Florida, 33761
United States
Research Center
Loma Linda, California, 92354
United States
Research Center
Des Moines, Iowa, 50309
United States
Research Center
Lexington, Kentucky, 40503
United States
Research Center
Tampa, Florida, 33609
United States
Research Center
Oceanside, California, 92056
United States
Research Center
Portland, Oregon, 97209
United States
Research Center
Marietta, Georgia, 30060
United States
Research Center
Scarborough, Maine, 04074
United States
Research Center
Oxnard, California, 93030
United States
Research Center
LaJolla, California, 92037
United States
Research Center
Southfield, Michigan, 48034
United States
Research Center
Tampa, Florida,
United States
Research Center
Asheville, North Carolina, 28803
United States
Research Center
Crestview, Kentucky, 41017
United States
Research Center
Canfield, Ohio, 44406
United States
Research Center
San Antonio, Texas, 78229
United States
Research Center
La Jolla, California, 92037
United States
Research Center
Louisville, Kentucky, 40202
United States
Research Center
Upland, Pennsylvania, 19013
United States
Research Center
St. Petersburg, Florida, 33701
United States
Research Center
Winston Salem, North Carolina, 27103
United States
Research Center
La Jolla, California, 92037
United States
Research Center
Tampa, Florida, 33614
United States
Research Center
Savannah, Georgia, 31405
United States
Research Center
Little Rock, Arkansas, 72205
United States
Research Center
Sunnyvale, California, 94089
United States
Research Center
Jacksonville, Florida, 32216
United States
Research Center
Lakeland, Florida, 33805
United States
Research Center
Dubuque, Iowa, 52001
United States
Research Center
Palm Beach Gardens, Florida, 33410
United States
Research Center
Carolina, , 00983
Puerto Rico
Research Center
Little Rock, Arkansas, 72205
United States
Research Center
Eugene, Oregon, 97401
United States
Research Center
Carolina, , 00983
Puerto Rico
Research Center
Ft. Lauderdale, Florida, 33308
United States
Research Center
Sharon, Massachusetts, 02067
United States
Research Center
Tacoma, Washington, 98405
United States
Research Center
Irvine, California, 92618
United States
Research Center
Tallahassee, Florida, 32308
United States
Research Center
Ponce, , 00731
Puerto Rico
Additional Information:
Study ID Numbers: DA2APD-0075-031;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00058838
Other Parkinson Disease Studies:
1. Study of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease
2. Chinese Exercise Modalities in Parkinson's Disease
3. GM1 Ganglioside Effects on Parkinson’s Disease
4. Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
5. Donepezil to Treat Dementia in Parkinson's Disease
Related Studies:
Other Parkinson Disease Clinical Trials
Other Massachusetts Clinical Trials
Other Sharon Clinical Trials
A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease
|
|
|
|
|
|
|
|